Novavax Inc. (NASDAQ:NVAX) finished Thursday with a subtraction of -$3.43 to close at $22.44, a downside of -13.26 percent. An average of 5,332,580 shares of common stock have been traded in the last five days. There was a fall of -$10.11 in the past week, and it reached a new high 1 time over the past 12 months. The last 20 days have seen an average of 4,059,695 shares traded, while the 50-day average volume stands at 6,028,486.
NVAX stock has decreased by -38.60% in the last month. The company shares reached their 1-month lowest point of $21.81 on 09/22/22. With the stock rallying to its 52-week high on 01/03/22, shares of the company touched a low of $25.84 and a high of $260.69 in 52 weeks. It has reached a new high 1 time so far this year and lost -84.32% or -$120.63 in price. In spite of this, the price is down -91.39% from the 52-week high.
Top 5 Cheap Stocks to Own Right Now
While finding safe stocks with the potential for monster gains isn't always easy, we've found a few that could pay out well. In fact, within our report, "Top 5 Cheap Stock to Own Right Now", we have identified five stocks we believe could appreciate the most even if you just have $1,000 to invest.
Sign up here to get your free report now. .
176 days have passed since Novavax Inc. (NVAX) last reported insider trading activity. YOUNG JAMES F, who is Director, most recently acquired $12,500 shares at $73.58 per share on Mar 31. In this transaction, the insider spent $919,765. EVP, Chief Legal Officer, Herrmann John A III, disposed of 5,000 shares at a price of $140.91 on Jan 03. The insider now owns more than $704,534 worth of shares. Prior to that, Director YOUNG JAMES F went on to Sale 3,750 shares at $144.16 each on Dec 31. An amount of $540,601 was transacted.
Novavax Inc. (NVAX) stock’s beta is 1.65. Other valuation ratios to consider include the trailing price-to-sales (P/S) ratio at 1.46.
The quick ratio of Novavax Inc. for the three months ended June 29 was 0.90, and the current ratio was 1.00, indicating that the company is not able to meet its debt obligations. Its gross profit as reported stood at $2.83 billion compared to revenue of $1.15 billion.
For investors, determining the potential profitability of the investment also depends on the performance of the company’s management. In the past 12 months, Novavax Inc.’s return on assets was -55.70%.
In the quarter under review, the net income was down than the previous quarter. The company posted a net income of -$510.49 million in the quarter, while revenues were grew 30.98%. The analyst consensus anticipated Novavax Inc.’s latest quarter earnings to come in at $5.5 per share, but it turned out to be -$6.53, a -218.70% surprise. For the quarter, EBITDA amounted to -$476.24 million. Shareholders own equity worth $78.22 million.
From a technical analysis perspective, let’s take a brief look at Novavax Inc. (NVAX) price momentum. RSI 9-day as of the close on 22 September was 20.20%, suggesting the stock is oversold, with historical volatility in this time frame at 86.70%.
As of today, NVAX’s price is $26.92 -31.06% or -$10.11 from its 5-day moving average. NVAX is currently trading -39.47% lower than its 20-day SMA and -49.31% lower than its 100-day SMA. However, the stock’s current price level is -67.92% below the SMA50 and -86.02% below the SMA200.
The stochastic %K and %D were 2.91% and 6.74%, respectively, and the average true range (ATR) was 2.66. With the 14-day stochastic at 5.45% and the average true range at 2.92, the RSI (14) stands at 25.82%. The stock has reached -4.02 on the 9-day MACD Oscillator while the 14-day reading was at -4.39.
JP Morgan downgraded Novavax Inc. (NASDAQ: NVAX) to a an Underweight rating in its most recent analyst report. Previously, the stock was rated as a Neutral.